Magazine Article | March 5, 2019

IO Building A New Future For Cancer Treatment

Source: Cell & Gene

By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter

Immuno-oncology (IO) – stimulating the immune system against cancer – could arguably date back to 2600 BC, where infection was used to trigger tumor regression, or to the 1890s, with Coley’s toxins, a mixture of killed bacteria. After over a century of quiet, IO is moving forward rapidly.

The current era of IO began with the 2010 approval of Provenge (sipuleucel-T), a personalized dendritic cell therapy for the treatment of prostate cancer, and the 2011 approval of Bristol-Myers Squibb’s Yervoy (ipilimumab). “The advent of immuno-oncology has heralded a revolution in cancer therapy,” said Asthika Goonewardene, senior biotech analyst at Bloomberg Intelligence.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: